In one case report, anti-IL-17A treatment was beneficial for preventing the development of an autoimmune disease in a patient, but at the same time, it caused the loss of an antitumor response in the same patient who also suffered from CRC [54]. This evidence concerns the gene IL17A and autoimmune disease.